NCT01580501View on ClinicalTrials.gov

PDE Inhibitors in DMD Study (Acute Dosing Study)

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

March 31, 2013

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

Tadalafil and Sildenafil

PDE-5 Inhibitor; Low dosages will be 0.5mg/kg and high dosages will be 1.0mg/kg

Trial Locations (1)

90048

Cedars Sinai Medical Center, Los Angeles

All Listed Sponsors
lead

Cedars-Sinai Medical Center

OTHER

NCT01580501 - PDE Inhibitors in DMD Study (Acute Dosing Study) | Biotech Hunter | Biotech Hunter